Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  4,626 results for ""TYROSINE KINASE INHIBITORS""

Your Filters

Content Provider : MEDLINE
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors.

  • Authors : Mavridis E; Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.; Hadjipavlou-Litina D

Subjects: Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/chemistry ; Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/pharmacokinetics ; Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/pharmacology

  • Source: International journal of molecular sciences [Int J Mol Sci] 2025 Oct 20; Vol. 26 (20). Date of Electronic Publication: 2025 Oct 20.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.

  • Authors : Oiki H; Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan.; Suda K

Subjects: Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/pharmacology ; Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/therapeutic use ; Mutation*/Mutation*/Mutation*/genetics

  • Source: Cells [Cells] 2025 Sep 04; Vol. 14 (17). Date of Electronic Publication: 2025 Sep 04.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Expanded CD16 + CD56 + Granzyme B + NK like CD8 + T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia.

Subjects: CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/immunology ; CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/drug effects ; CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/metabolism

  • Source: Scientific reports [Sci Rep] 2025 Oct 05; Vol. 15 (1), pp. 34641. Date of Electronic Publication: 2025 Oct 05.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.

  • Authors : Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Hehlmann R

Subjects: Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/therapeutic use ; Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/pharmacology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy

  • Source: Leukemia & lymphoma [Leuk Lymphoma] 2025 Sep; Vol. 66 (9), pp. 1615-1624. Date of Electronic Publication: 2025 Jun 22.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Electric Field-Driven Modulation of Nanomechanical Interactions Between Tyrosine Kinase Inhibitors and Human Serum Albumin: Insights from AFM-Based Force Spectroscopy.

  • Authors : Fu Y; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.; Wang J

Subjects: Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/chemistry ; Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/pharmacology ; Serum Albumin, Human*/Serum Albumin, Human*/Serum Albumin, Human*/chemistry

  • Source: Molecules (Basel, Switzerland) [Molecules] 2025 Aug 30; Vol. 30 (17). Date of Electronic Publication: 2025 Aug 30.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?

  • Authors : Lin HW; School of Pharmacy and Graduate Institute, China Medical University, Taichung, Taiwan.; Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan.

Subjects: Neoplasms*/Neoplasms*/Neoplasms*/drug therapy ; Long QT Syndrome*/Long QT Syndrome*/Long QT Syndrome*/chemically induced ; Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/adverse effects

  • Source: BMC medical informatics and decision making [BMC Med Inform Decis Mak] 2025 Aug 15; Vol. 25 (1), pp. 310. Date of Electronic Publication: 2025 Aug 15.Publisher: BioMed Central Country of Publication: England NLM ID: 101088682 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6947

Record details

Read Online Read More Add to Saved list
×
Editorial & Opinion

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study.

  • Authors : Zhang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.; Huang Y

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use

  • Source: Journal of hematology & oncology [J Hematol Oncol] 2025 Jul 26; Vol. 18 (1), pp. 75. Date of Electronic Publication: 2025 Jul 26.Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Design, Docking Analysis, and Structure-Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions.

  • Authors : Philipova I; Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bontchev Str. Bl. 9, 1113 Sofia, Bulgaria.; Atanasova M

Subjects: Metallocenes*/Metallocenes*/Metallocenes*/chemistry ; Metallocenes*/Metallocenes*/Metallocenes*/pharmacology ; Ferrous Compounds*/Ferrous Compounds*/Ferrous Compounds*/chemistry

  • Source: Molecules (Basel, Switzerland) [Molecules] 2025 Jul 24; Vol. 30 (15). Date of Electronic Publication: 2025 Jul 24.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.

  • Authors : Chai X; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.; Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing, China.

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

  • Source: Journal of translational medicine [J Transl Med] 2025 Aug 18; Vol. 23 (1), pp. 933. Date of Electronic Publication: 2025 Aug 18.Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Exploiting collateral sensitivity in the evolution of resistance to tyrosine kinase inhibitors in soft tissue sarcomas.

  • Authors : Elms ML; Division of Cancer Biology, The Institute of Cancer Research, London, UK.; Jenks AD

Subjects: Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/drug effects ; Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/pharmacology ; Sarcoma*/Sarcoma*/Sarcoma*/drug therapy

  • Source: Communications biology [Commun Biol] 2025 Aug 08; Vol. 8 (1), pp. 1185. Date of Electronic Publication: 2025 Aug 08.Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
  • 1-10 of  4,626 results for ""TYROSINE KINASE INHIBITORS""